Fulvestrant

Drugs

Volumn 61, Issue 6, 2001, Pages 807-813

  Curran, M ^a   Wiseman, L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FULVESTRANT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; NONHUMAN; POSTMENOPAUSE; PROTEIN DEGRADATION; TRANSCRIPTION REGULATION;

ANIMALIA;

EID: 0034991565     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161060-00013     Document Type: Article

References (32)

1. A potent specific pure antiestrogen with clinical potential
2. Steroidal pure antioestrogens
3. Action of "pure" antiestrogens inhibiting estrogen receptor action
4. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization
5. The mechanism of ICI 164384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
6. Antiestrogenic ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
7. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
8. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells
9. 1
10. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells
11. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment
12. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
13. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780
14. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
15. Effects of 4-hydroxytamoxifen and a novel pure antioes trogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro
16. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780
17. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity
18. Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): Quantitative magnetic resonance imaging
19. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats
20. 17 β-estradiol increases calcium content in fetal mouse parietal bones cultured in serum-free medium only at physiological concentrations
21. The future of new pure antiestrogens in clinical breast cancer
22. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
23. Comparison of the short-term biological effects of fulvestrant (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer
24. Pharmacokinetics, pharmacological and anti-turnout effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
25. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women
26. A comparison of the single-dose pharmacokinetics of "Faslodex" (fulvestrant) 250 mg when given as either a one x 5-ml intra-muscular injection or two x 2.5-ml injections in postmenopausal women with advanced breast cancer
27. The pharmacokinetics of single dose faslodex (TM) (ICI 182,780) in postmenopausal primary breast cancer - Relationship with estrogen receptor down regulation
28. ICI I82,780 ("Falsodex") (FAS) 250 mg monthly intramuscular (i.m.) injection shows consistent PK during long-term dosing in postmenopausal women with advanced breast cancer (ABC)
29. "Faslodex" (ICI 182,780) shows longer duration of response compared with "arimidex" (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC). Preliminary results of a phase III North American trial
30. TM) in post-menopausal women with advanced breast cancer (ABC) - Preliminary results
31. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
32. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer